MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
LivaNova PLC Long-Term Debt 2011-2026 | LIVN
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt LivaNova PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 345 M | 550 M | 569 M | 518 M | 9.85 M | 642 M | 260 M | 140 M | 62 M | 75.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 642 M | 9.85 M | 317 M |
Quarterly Long-Term Debt LivaNova PLC
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 349 M | 348 M | 549 M | 550 M | - | 605 M | 605 M | 569 M | 568 M | 568 M | 520 M | 518 M | 518 M | - | 456 M | 9.85 M | 10.8 M | 431 M | 646 M | 642 M | 642 M | 639 M | 642 M | 260 M | 260 M | 260 M | 260 M | 140 M | 140 M | 140 M | 140 M | 62 M | 62 M | 62 M | 62 M | 75.2 M | 75.2 M | 75.2 M | 75.2 M | 91.8 M | 91.8 M | 91.8 M | 91.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 646 M | 9.85 M | 315 M |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apyx Medical Corporation
APYX
|
34.8 M | $ 3.72 | 0.95 % | $ 153 M |  USA |
 |
AxoGen
AXGN
|
48.4 M | $ 33.03 | -4.08 % | $ 1.52 B | USA |
 |
Butterfly Network
BFLY
|
20.4 M | $ 4.07 | -1.09 % | $ 862 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.72 B | $ 12.25 | 1.79 % | $ 1.66 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B | USA |
 |
Bruker Corporation
BRKR
|
2.06 B | $ 36.66 | -0.27 % | $ 5.46 K | USA |
 |
Boston Scientific Corporation
BSX
|
11.1 B | $ 62.57 | -0.4 % | $ 92.6 B | USA |
 |
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | USA |
 |
Acutus Medical
AFIB
|
32.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
7.56 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
3.59 M | - | 1.37 % | $ 20.5 M | USA |
 |
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | USA |
 |
ClearPoint Neuro
CLPT
|
49.1 M | $ 9.41 | 0.48 % | $ 266 M | USA |
 |
CONMED Corporation
CNMD
|
834 M | $ 34.54 | -0.72 % | $ 1.07 B | USA |
 |
Cytosorbents Corporation
CTSO
|
16.7 M | $ 0.62 | 5.64 % | $ 38.6 M | USA |
 |
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | USA |
 |
Delcath Systems
DCTH
|
835 K | $ 9.76 | 1.35 % | $ 350 M | USA |
 |
EDAP TMS S.A.
EDAP
|
2 M | $ 3.5 | 3.24 % | $ 131 M |  France |
 |
Cardiovascular Systems
CSII
|
1.33 M | - | 0.15 % | $ 844 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
598 M | $ 81.26 | 0.26 % | $ 47.5 B | USA |
 |
Cutera
CUTR
|
1.06 M | - | -10.19 % | $ 1.99 M | USA |
 |
FONAR Corporation
FONR
|
155 K | $ 18.6 | 0.04 % | $ 122 M | USA |
 |
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | USA |
 |
Align Technology
ALGN
|
88.2 M | $ 170.52 | -0.05 % | $ 12.8 B | USA |
 |
Helius Medical Technologies
HSDT
|
12 K | $ 1.87 | 0.27 % | $ 1.14 M | USA |
 |
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
760 M | $ 9.31 | -2.31 % | $ 717 M | USA |
 |
Inogen
INGN
|
14.3 M | $ 6.42 | 3.38 % | $ 171 M | USA |
 |
IRIDEX Corporation
IRIX
|
98 K | $ 0.99 | 1.47 % | $ 16.8 M | USA |
 |
IRadimed Corporation
IRMD
|
2 K | $ 96.6 | 0.38 % | $ 1.23 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.19 B | $ 85.01 | -2.12 % | $ 2.95 B | USA |
 |
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B |  Israel |
 |
OrthoPediatrics Corp.
KIDS
|
99.8 M | $ 15.95 | -0.68 % | $ 374 M | USA |
 |
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
7.64 M | - | - | $ 111 M |  Canada |
 |
Second Sight Medical Products
EYES
|
17.1 M | - | -0.97 % | $ 54.4 M | USA |
 |
LENSAR
LNSR
|
1.99 M | $ 5.97 | -1.49 % | $ 71.4 M | USA |
 |
Pulmonx Corporation
LUNG
|
37 M | $ 1.38 | 3.38 % | $ 56.1 M | USA |
 |
Medtronic PLC
MDT
|
25.6 B | $ 86.52 | -0.13 % | $ 111 B | USA |
 |
MiMedx Group
MDXG
|
16.5 M | $ 3.89 | -0.89 % | $ 575 M | USA |
 |
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | USA |
 |
Myomo
MYO
|
11.2 M | $ 0.69 | 3.22 % | $ 28.9 M | USA |